<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04461691</url>
  </required_header>
  <id_info>
    <org_study_id>POLAR-HF</org_study_id>
    <nct_id>NCT04461691</nct_id>
  </id_info>
  <brief_title>Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation With Heart Failure</brief_title>
  <acronym>POLAR-HF</acronym>
  <official_title>Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Josefs-Hospital Wiesbaden GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Josefs-Hospital Wiesbaden GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of atrial fibrillation (AF) and heart failure (HF) is common and implies a
      poor prognosis. Pulmonary vein isolation is an established method for the treatment of
      symptomatic AF in patients with normal heart function and has been shown to be more effective
      than drug therapy. Recently, radiofrequency ablation has shown a positive effect in patients
      with AF and HF. POLAR-HF has been designed to investigate efficacy and safety of cryoballoon
      pulmonary vein isolation in patients with paroxysmal or persistent AF and severe HF (LVEF ≤
      40%).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measures (Number of recurrence)</measure>
    <time_frame>36 months</time_frame>
    <description>Number of subjects with recurrence of atrial fibrillation or re-ablation after a blanking Period of 90 days after the initial cryoablation procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome Measures (number of safety events)</measure>
    <time_frame>36 months</time_frame>
    <description>2. Number of subjects with a primary safety event including a composite of death from any cause, stroke or transient ischemic attack and serious procedure-related adverse events (Major Bleeding by International Society on Thrombosis and Hemostasis (ISTH) criteria, pericardial effusion, cerebrovascular or systemic embolism, phrenic paresis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (number of deaths)</measure>
    <time_frame>36 months</time_frame>
    <description>Number of all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (procedural success)</measure>
    <time_frame>36 months</time_frame>
    <description>2. Incidence of acute procedural success assessed by successful isolation of all pulmonary veins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (rehospitalization)</measure>
    <time_frame>36 months</time_frame>
    <description>3. Number of subjects reporting a first unplanned rehospitalization for cardiovasvular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (procedure duration)</measure>
    <time_frame>36 months</time_frame>
    <description>4. Total procedure duration and left-atrial dwell time (in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (total time)</measure>
    <time_frame>36 months</time_frame>
    <description>5. Total fluoroscopy time (in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures (total contrast use)</measure>
    <time_frame>36 months</time_frame>
    <description>6. Total contrast dye use (in milliliters)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <condition>Cryoballon Ablation</condition>
  <arm_group>
    <arm_group_label>Heart Failure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal cardiac function</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoballoon Pulmonary Vein Isolation</intervention_name>
    <description>Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.</description>
    <arm_group_label>Heart Failure</arm_group_label>
    <arm_group_label>Normal cardiac function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic paroxysmal or persistent atrial fibrillation

          -  Patients with severe heart failure (LVEF ≤40%, assigned to heart failure group)

          -  Patients with normal cardiac function (assigned to control group)

          -  Age &gt; 18 years

          -  Consent capacity

        Exclusion Criteria:

          -  Age under 18 years

          -  Pregnancy

          -  Lack of consent capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Josefs-Hospital Wiesbaden GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Ehrlich, Prof. Dr.</last_name>
      <phone>+496111771201</phone>
      <email>jehrlich@joho.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Boehmer, Dr. med.</last_name>
      <phone>+496111771201</phone>
      <email>aboehmer@joho.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

